Reed Jobs would rather talk about curing cancer than his last name
When we last sat down with Jobs at TechCrunch Disrupt nearly three years ago, his firm Yosemite was brand new and biotech was still reeling from its post-pandemic crash. Now, the venture outfit has a…
Read the full articleYou might also wanna read
Reed Jobs Would Rather Talk About Curing Cancer Than His Last Name
When we last sat down with Jobs at TechCrunch Disrupt nearly three years ago, his firm Yosemite was brand new and biotech was still reeling
Reed Jobs on AI, undruggable cancer targets, and building Yosemite into a biotech powerhouse
Reed Jobs, founder of the oncology-focused venture firm Yosemite, doesn’t want to talk about his last name. He’d rather discuss Yosemite, th
Yosemite's AI Leap: Biotech's New Frontier
Yosemite's team has expanded to 17, riding the wave of AI's transformation in biotech. The loss of patent protections on key drugs presents
Reed Jobs Focuses on Cancer Research Over Family Legacy
During a recent chat at TechCrunch Disrupt, Reed Jobs, son of the late Steve Jobs, shared insights about his evolving role in the biotech se
Is Big Tech Now Backpedaling on the AI Jobs Wipeout Scenario?
"A year ago, the message from many business leaders was that AI was going to wipe out jobs," remembers the Wall Street Journal.But "For the
US biotechs turn secretive as they fear competition from rising Chinese industry
US biotechs turn tight-lipped on gene targets and pipelines as China's fast-follower threat intensifies, 20+ founders and investors tell End
endpoints.news·6d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.